Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions

Cancer

Volumn 113, Issue 1, 2008, Pages 135-142

  Cooper, Wendy A ^a   Kohonen Corish, Maija R J ^b   Zhuang, Liqing ^a,c   McCaughan, Brian ^a   Kennedy, Catherine ^d   Screaton, Gavin ^e   Sutherland, Robert L ^b   Lee, C Soon ^c,f  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c University of Sydney   (Australia)

^d Strathfield Private Hospital   (Australia)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Immunohistochemistry; Nonsmall cell lung carcinoma; Prognosis; TRAIL receptor

Indexed keywords

DEATH RECEPTOR 5;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL METAPLASIA; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SURVIVAL ANALYSIS;

EID: 47149091701     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23528     Document Type: Article

References (43)

1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153.
2. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF-family that induces apoptosis. Immunity. 1995;3:673-682.
3. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
4. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998;161:2833-2840.
5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821.
6. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene. 2007;26:3745-3757.
7. Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005;25:1430-1441.
8. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer. 2006;42:2233.
9. Booth CM, Shepherd FA. Adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol. 2006;1:180-187.
10. Nesbitt JC, Putnam JB, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995;60:466.
11. Han JY, Hong EK, Choi BG, et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small cell lung cancer. Med Oncol. 2003;20:355-362.
12. Spierings DCJ, de Vries EGE, Timens W, Groen HJM, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397-3405.
13. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.). World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
14. Grondin SC, Liptay MJ. Current concepts in the staging of non-small cell lung cancer. Surg Oncol. 2002;11:181-190.
15. Cooper WA, Kohonen-Corish MRJ, Chan C, et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small cell lung cancer and precursor lesions. Histopathology. 2008;52:613-622.
16. Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005;15:430-438.
17. Zhuang L, Lee CS, Scolyer RA, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol. 2006;37:1286-1294.
18. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol. 2003;200:327-335.
19. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clin Cancer Res. 2005;11:5188-5194.
20. Reesink-Peters N, Hougardy BM, Van den Heuvel FA, et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynaecol Oncol. 2005;96:705-713.
21. Ozawa F, Friess H, Kleef J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Letters.2001:71-81.
22. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001;61:3330-3338.
23. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004;52:821-831.
24. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and - independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593-1598.
25. Horak P, Pils D, Kaider A, et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res. 2005;11:8585-8591.
26. van Geelen CM, Westra JL, de Vries EG, et al. Prognosti significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol. 2006;24:4998-5004.
27. Bennett M, Macdonald K,Chan S-W, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53 mediated apoptosis. Science. 1998;282:290-293.
28. Jones SJ, Ledgerwood EC, Prins JB, et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol. 1999;162:1042-1048.
29. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol. 2000;164:3961-3970.
30. Strater J, Hinz U, Walczak H, et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res. 2002;8:3734-3740.
31. Min YJ, Lee J-H, Choi S-J, et al. Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk Res. 2004;28:359.
32. Baader E, Toloczko A, Fuchs U, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 2005;65:7888-7895.
33. Tran SEF, Holmstrom TH, Ahonen M,Kahari V-M, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem. 2001;276:16484-16490.
34. Tran SEF, Meinander A, Eriksson JE. Instant decisions: transcription-independent control of death-receptor-mediated apoptosis. Trends Biochem Sci. 2004;29:601.
35. Franco AV, Zhang XD, Van Berkel E, et al. The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol. 2001;166:5337-5345.
36. Austin CD, Lawrence DA, Peden AA, et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA. 2006;103:10283-10288.
37. Jin Z, McDonald ER, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 2004;279:35829-35839.
38. Kohlhaas SL, Craxton A, Sun X, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem. 2007;282:12831-12841.
39. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003;10:356.
40. Fulda S, Meyer E, Debatin K-M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2002;21:2283-2294.
41. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190.
42. Kim K, Fisher MJ, Xu S-Q, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000;6:335-346.
43. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol. 1999;162:2597-2605.